Wendy Becker Buys 536 Shares of GSK plc (LON:GSK) Stock

GSK plc (LON:GSK) insider Wendy Becker purchased 536 shares of the company’s stock in a transaction that occurred on Thursday, March 20th. The shares were purchased at an average cost of GBX 1,515 ($19.56) per share, with a total value of £8,120.40 ($10,486.05).

GSK Trading Down 0.1 %

GSK stock opened at GBX 1,509 ($19.49) on Monday. The firm’s fifty day simple moving average is GBX 1,441.42 and its two-hundred day simple moving average is GBX 1,437.45. The stock has a market capitalization of £61.23 billion, a price-to-earnings ratio of 24.38, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31. The company has a quick ratio of 0.73, a current ratio of 0.81 and a debt-to-equity ratio of 114.64. GSK plc has a twelve month low of GBX 1,282.50 ($16.56) and a twelve month high of GBX 1,823.50 ($23.55).

GSK (LON:GSK) last issued its quarterly earnings results on Wednesday, February 5th. The company reported GBX 23.20 ($0.30) EPS for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. As a group, analysts anticipate that GSK plc will post 175.980975 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on GSK. Berenberg Bank lowered their target price on GSK from GBX 1,820 ($23.50) to GBX 1,600 ($20.66) and set a “buy” rating for the company in a research report on Friday, November 29th. JPMorgan Chase & Co. reissued an “underweight” rating on shares of GSK in a research note on Tuesday, January 7th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, GSK currently has a consensus rating of “Moderate Buy” and an average target price of GBX 1,805.83 ($23.32).

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.